Proposed biosimilar shows equivalence to golimumab in rheumatoid arthritis
A biosimilar for golimumab has demonstrated therapeutic equivalence in rheumatoid arthritis, with no clinically meaningful safety differences, according to a press release from the manufacturer. The topline results, announced by Alvotech, stem from a confirmatory clinical study for AVT05, the company’s proposed biosimilar to the TNF alpha inhibitors Simponi and Simponi Aria (golimumab,